

# Andrea Feyereislova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10727055/publications.pdf>

Version: 2024-02-01

9  
papers

13,161  
citations

1039406

9  
h-index

1372195

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

12689  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet, The</i> , 2010, 376, 687-697.	6.3	5,899
2	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2237-2246.	0.8	2,822
3	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. <i>Lancet, The</i> , 2007, 369, 29-36.	6.3	1,361
4	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet, The</i> , 2010, 375, 377-384.	6.3	1,061
5	ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 2240-2250.	0.8	750
6	Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5529-5537.	0.8	746
7	Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition. <i>Journal of Clinical Oncology</i> , 2002, 20, 110-124.	0.8	441
8	Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. <i>PLoS ONE</i> , 2019, 14, e0209709.	1.1	41
9	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well Tolerated. <i>Journal of Clinical Oncology</i> , 2010, 28, 960-966.	0.8	37